Concepedia

Publication | Open Access

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

DOIFull Paper Access

10

Citations

22

References

2022

Year

Cara Mathews, Domenica Lorusso, Robert L. Coleman, Susan Boklage, Jamie Garside
The Oncologist

Abstract

This ITC suggests a favorable benefit:risk profile for dostarlimab in patients with dMMR/MSI-H advanced/recurrent EC.

References

YearCitations

Page 1